Tagraxofusp

Elzonris

Near Add Your Location

Sorting 4 by

Accepting patients

SL-401

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 1

Accepting patients

Tagraxofusp

CD123 Antibody Toxin Congregate (CD123 ATC; Tagraxofusp) Combined With Azacitidine for Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for Patients With CD123-Positive Malignant
  • CD123
  • Post-Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Tagraxofusp in Combination With Decitabine

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
  • CD123
  • Phase 1/2

Accepting patients

Tagraxofusp for Post-Transplant Maintenance

Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia
  • CD123
  • Maintenance
  • Post-Allogeneic Stem Cell Transplant
  • Phase 1